IP Library Granted Patent US 9,084,828
Granted Patent B2
US 9,084,828 · App. 14/336,764 · Granted Jul 21, 2015

Oligomer-protein tyrosine kinase inhibitor conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,828
App. No.
14/336,764
Granted
Jul 21, 2015
Kind
B2
Abstract

The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.

Claims (11)

1. A method for inhibiting a protein tyrosine kinase, the method comprising administering to a mammal a protein tyrosine kinase-inhibiting amount of a compound having the following structure

or a pharmaceutically acceptable salt thereof, wherein X is a spacer moiety and POLY is a water-soluble, non-peptidic oligomer having from about 1 to about 30 monomers.

2. The method of claim 1 , wherein X is a spacer moiety that includes a bivalent peptidic moiety of an amino acid.

3. The method of claim 1 , wherein the water-soluble, non-peptidic oligomer is a poly(alkylene oxide).

4. The method of claim 3 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).

5. The method of claim 1 , wherein the water-soluble, non-peptidic oligomer has from about 1 to about 10 monomers.

6. The method of claim 1 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

7. The method of claim 1 , wherein the compound has the following structure

wherein n is 1 to 30; and X is a peptidic moiety of a bivalent amino acid.

8. The method of claim 1 , wherein the compound has a structure selected from the group consisting of:

wherein n is 1 to 30.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 33760, FRAME 0791 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036865/0265 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY INTEREST Recorded Sep 17, 2014
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 033760/0791 →